
Susanna Moore
Examiner (ID: 3539, Phone: (571)272-9046 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624 |
| Total Applications | 1893 |
| Issued Applications | 1112 |
| Pending Applications | 183 |
| Abandoned Applications | 626 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20864214
[patent_doc_number] => 12691084
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-07-28
[patent_title] => Pharmaceutical composition for preventing or treating bone diseases
[patent_app_type] => utility
[patent_app_number] => 17/627914
[patent_app_country] => US
[patent_app_date] => 2020-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 14
[patent_no_of_words] => 5317
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17627914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/627914 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES | Jul 12, 2020 | Pending |
Array
(
[id] => 18666231
[patent_doc_number] => 11773109
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-03
[patent_title] => Composition for hardening soft tissue
[patent_app_type] => utility
[patent_app_number] => 16/925043
[patent_app_country] => US
[patent_app_date] => 2020-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 8
[patent_no_of_words] => 8823
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925043
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/925043 | Composition for hardening soft tissue | Jul 8, 2020 | Issued |
Array
(
[id] => 16398728
[patent_doc_number] => 20200339586
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => Compounds And Their Use As Inhibitors Of N-Myristoyl Transferase
[patent_app_type] => utility
[patent_app_number] => 16/923133
[patent_app_country] => US
[patent_app_date] => 2020-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16923133
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/923133 | Compounds and their use as inhibitors of N-myristoyl transferase | Jul 7, 2020 | Issued |
Array
(
[id] => 16512874
[patent_doc_number] => 20200392132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => Tetrahydro-Pyrido-Pyrimidine Derivatives
[patent_app_type] => utility
[patent_app_number] => 16/916168
[patent_app_country] => US
[patent_app_date] => 2020-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44047
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16916168
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/916168 | Tetrahydro-Pyrido-Pyrimidine Derivatives | Jun 29, 2020 | Abandoned |
Array
(
[id] => 17913210
[patent_doc_number] => 20220315605
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OF
[patent_app_type] => utility
[patent_app_number] => 17/623041
[patent_app_country] => US
[patent_app_date] => 2020-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4990
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17623041
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/623041 | IMPROVED PROCESS FOR THE PREPARATON OF PURE (1'R,6R,6aR,7R,13S,14S,16R)-5-(ACETYLOXY)-3',4',6,6a,7,13,14,16-OCTAHYDRO-6',8,14-TRIHYDROXY-7',9-DIMETHOXY-4,10,23-TRIMETHYLSPIRO[6,16-(EPITHIOPROPANOXYMETH ANO)-7,13-IMINO-12H-1,3-DIOXOLO[7,8]ISOQUINO[3,2-b][3]BENZAZOCINE-20,1'(2'H)-ISOQUINOLIN]-19-ONE POLYMORPH THERE OF | Jun 28, 2020 | Abandoned |
Array
(
[id] => 18139583
[patent_doc_number] => 20230013419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE
[patent_app_type] => utility
[patent_app_number] => 17/620410
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620410
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/620410 | ANALOGUES OF 3-(5-METHYL-1,3-THIAZOL-2-YL)-N-{(1R)-1-[2-(TRIFLUORO-METHYL)PYRIMIDIN-5-YL]ETHYL}BENZAMIDE | Jun 24, 2020 | Abandoned |
Array
(
[id] => 18057862
[patent_doc_number] => 20220388948
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => PROCESS FOR THE PREPARATION OF A METASTABLE CRYSTAL MODIFICATION OF N-(AMINOIMINOMETHYL)-2-AMINOACETIC ACID (III)
[patent_app_type] => utility
[patent_app_number] => 17/621023
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621023
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/621023 | Process for the preparation of a metastable crystal modification of n-(aminoiminomethyl)-2-aminoacetic acid (III) | Jun 24, 2020 | Issued |
Array
(
[id] => 18028875
[patent_doc_number] => 11512047
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Metastable crystal modification and method for producing the same (I)
[patent_app_type] => utility
[patent_app_number] => 17/625494
[patent_app_country] => US
[patent_app_date] => 2020-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 7162
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625494
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/625494 | Metastable crystal modification and method for producing the same (I) | Jun 24, 2020 | Issued |
Array
(
[id] => 16376295
[patent_doc_number] => 20200325137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => IMIDAZOLONYLQUINOLINES AND THE USE THEREOF AS ATM KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/910438
[patent_app_country] => US
[patent_app_date] => 2020-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25048
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16910438
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/910438 | Imidazolonylquinolines and the use thereof as ATM kinase inhibitors | Jun 23, 2020 | Issued |
Array
(
[id] => 17774874
[patent_doc_number] => 20220241223
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-04
[patent_title] => USE OF DISULFIRAM OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION
[patent_app_type] => utility
[patent_app_number] => 17/620630
[patent_app_country] => US
[patent_app_date] => 2020-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8519
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620630
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/620630 | USE OF DISULFIRAM OR ITS DERIVATIVES FOR THE TREATMENT OF MITOCHONDRIAL DISEASES OR DYSFUNCTION | Jun 18, 2020 | Pending |
Array
(
[id] => 18044826
[patent_doc_number] => 11518767
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-06
[patent_title] => MTOR inhibitor compounds
[patent_app_type] => utility
[patent_app_number] => 16/907122
[patent_app_country] => US
[patent_app_date] => 2020-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 7954
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16907122
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/907122 | MTOR inhibitor compounds | Jun 18, 2020 | Issued |
Array
(
[id] => 17913197
[patent_doc_number] => 20220315592
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => EGFR INHIBITOR FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/620239
[patent_app_country] => US
[patent_app_date] => 2020-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620239
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/620239 | EGFR inhibitor for the treatment of cancer | Jun 18, 2020 | Issued |
Array
(
[id] => 16525191
[patent_doc_number] => 20200399271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS
[patent_app_type] => utility
[patent_app_number] => 16/905857
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39203
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16905857
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/905857 | Xanthine analogs as potent anti-West Nile viral agents | Jun 17, 2020 | Issued |
Array
(
[id] => 16688276
[patent_doc_number] => 20210070752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/904890
[patent_app_country] => US
[patent_app_date] => 2020-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 70480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904890
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/904890 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | Jun 17, 2020 | Abandoned |
Array
(
[id] => 17791987
[patent_doc_number] => 20220251078
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => Continuous Process for the Preparation of Anticholinergic Drugs
[patent_app_type] => utility
[patent_app_number] => 17/617725
[patent_app_country] => US
[patent_app_date] => 2020-06-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3588
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617725
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/617725 | Continuous Process for the Preparation of Anticholinergic Drugs | Jun 15, 2020 | Pending |
Array
(
[id] => 16816786
[patent_doc_number] => 11001592
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-11
[patent_title] => DNA polymerase IIIC inhibitors and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/901598
[patent_app_country] => US
[patent_app_date] => 2020-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74905
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16901598
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/901598 | DNA polymerase IIIC inhibitors and use thereof | Jun 14, 2020 | Issued |
Array
(
[id] => 17988823
[patent_doc_number] => 20220354860
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => HETEROCYCLIC DERIVATIVES AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/596674
[patent_app_country] => US
[patent_app_date] => 2020-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17397
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/596674 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | Jun 14, 2020 | Abandoned |
Array
(
[id] => 16343530
[patent_doc_number] => 20200308180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-01
[patent_title] => DNA Polymerase IIIC Inhibitors and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 16/901752
[patent_app_country] => US
[patent_app_date] => 2020-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 74897
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16901752
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/901752 | DNA polymerase IIIC inhibitors and use thereof | Jun 14, 2020 | Issued |
Array
(
[id] => 17807329
[patent_doc_number] => 20220259164
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-18
[patent_title] => USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT
[patent_app_type] => utility
[patent_app_number] => 17/618870
[patent_app_country] => US
[patent_app_date] => 2020-06-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17618870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/618870 | USE OF AMINOTHIOL COMPOUNDS AS CEREBRAL NERVE OR HEART PROTECTIVE AGENT | Jun 12, 2020 | Pending |
Array
(
[id] => 17792019
[patent_doc_number] => 20220251110
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => CGRP ANTAGONIST COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/617851
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29271
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617851
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/617851 | CGRP antagonist compounds | Jun 11, 2020 | Issued |